OTC Markets EXMKT - Delayed Quote USD
GB Sciences, Inc. (GBLX)
As of 9:45 AM EST. Market Open.
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Operating Expense
1,420.5090
1,420.5090
1,672.2810
1,868.7340
2,001.6170
Operating Income
-1,420.5090
-1,420.5090
-1,672.2810
-1,868.7340
-2,001.6170
Net Non Operating Interest Income Expense
-218.9730
-218.9730
-178.6520
-474.7680
-1,285.4600
Other Income Expense
277.8050
277.8050
-2,274.2610
2,196.9740
-45.7730
Pretax Income
-1,361.6770
-1,361.6770
-4,125.1940
-146.5280
-3,332.8500
Net Income Common Stockholders
-1,639.9920
-1,639.9920
-4,125.1940
-530.8730
-3,725.0270
Diluted NI Available to Com Stockholders
-1,639.9920
-1,639.9920
-4,125.1940
-530.8730
-3,725.0270
Basic EPS
-0.01
--
-0.01
-0.00
-0.01
Diluted EPS
-0.01
--
-0.01
-0.00
-0.01
Basic Average Shares
390,150.8160
--
357,721.1890
317,621.9420
285,190.7290
Diluted Average Shares
390,150.8160
--
357,721.1890
317,621.9420
285,190.7290
Total Operating Income as Reported
-1,420.5090
-1,420.5090
-1,672.2810
-1,868.7340
-2,001.6170
Total Expenses
1,420.5090
1,420.5090
1,672.2810
1,868.7340
2,001.6170
Net Income from Continuing & Discontinued Operation
-1,361.6770
-1,361.6770
-4,125.1940
-530.8730
-3,725.0270
Normalized Income
-1,319.4820
-1,319.4820
-1,750.9330
-2,295.1185
-3,514.6630
Interest Expense
218.9730
218.9730
178.6520
474.7680
1,285.4600
Net Interest Income
-218.9730
-218.9730
-178.6520
-474.7680
-1,285.4600
EBIT
-1,142.7040
-1,142.7040
-3,946.5420
328.2400
-2,047.3900
EBITDA
-1,142.0800
-1,142.0800
-3,884.8820
398.7280
-2,000.0370
Reconciled Depreciation
0.6240
0.6240
61.6600
70.4880
47.3530
Net Income from Continuing Operation Net Minority Interest
-1,361.6770
-1,361.6770
-4,125.1940
-146.5280
-3,332.8500
Total Unusual Items Excluding Goodwill
-42.1950
-42.1950
-2,374.2610
2,187.9740
181.8130
Total Unusual Items
-42.1950
-42.1950
-2,374.2610
2,187.9740
181.8130
Normalized EBITDA
-1,099.8850
-1,099.8850
-1,510.6210
-1,789.2460
-2,181.8500
Tax Rate for Calcs
--
--
--
0.0000
--
Tax Effect of Unusual Items
--
--
--
39.3835
--
3/31/2021 - 12/29/2003
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACXP Acurx Pharmaceuticals, Inc.
1.8201
-1.62%
TCRT Alaunos Therapeutics, Inc.
2.0400
+1.49%
PHRRF PharmaTher Holdings Ltd.
0.1661
-3.43%
INM InMed Pharmaceuticals Inc.
0.2250
0.00%
CLRB Cellectar Biosciences, Inc.
2.0508
+1.02%
NBY NovaBay Pharmaceuticals, Inc.
0.7376
-2.30%
CLSD Clearside Biomedical, Inc.
1.0900
+1.87%
AFMD Affimed N.V.
3.7300
+1.92%
MDXG MiMedx Group, Inc.
7.41
+1.65%
APVO Aptevo Therapeutics Inc.
0.2563
-4.37%